©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2025; 31(39): 108853
Published online Oct 21, 2025. doi: 10.3748/wjg.v31.i39.108853
Published online Oct 21, 2025. doi: 10.3748/wjg.v31.i39.108853
Strategies to prevent Barrett’s esophagus associated esophageal adenocarcinoma
Dashmeet M Singh, Arvind J Trindade, Rutgers University School of Medicine, Division of Gastroenterology, Robert Wood Johnson University Hospital, RWJBarnabas Health, New Brunswick, NJ 08901, United States
Author contributions: Singh DM and Trindade AJ contributed equally to this work. Trindade AJ and Singh DM conducted the literature review, did the analysis, interpretation of data and drafted the original manuscript. All authors prepared the draft and approved the submitted version.
Conflict-of-interest statement: Trindade AJ reports personal fees from Lucid Diagnostics, personal fees from Exact Science, outside the submitted work.
Corresponding author: Arvind J Trindade, MD, Professor, Rutgers University School of Medicine, Division of Gastroenterology, Robert Wood Johnson University Hospital, RWJBarnabas Health, 1 Robert Wood Johnson Place, MEB401b, New Brunswick, NJ 08901, United States. arvind.trindade@gmail.com
Received: April 25, 2025
Revised: June 30, 2025
Accepted: September 12, 2025
Published online: October 21, 2025
Processing time: 180 Days and 6 Hours
Revised: June 30, 2025
Accepted: September 12, 2025
Published online: October 21, 2025
Processing time: 180 Days and 6 Hours
Core Tip
Core Tip: The incidence of Barrett’s esophagus associated esophageal adenocarcinoma continues to rise. Several factors contribute to this problem, including a lack of recognition of high-risk patients, inconsistent screening mechanisms, and ineffective endoscopic evaluation and management of recognized disease. In this review, we provide a comprehensive and multifaceted overview of strategies to improve in all three domains to help prevent esophageal adenocarcinoma.